{"id":"W4405045833","doi":"10.1182/blood-2024-200966","title":"POIESIS: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Global Phase 3 Study of Navtemadlin As Add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients with Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Daiichi Sankyo Europe; Genentech; Swedish Orphan Biovitrum; Servier; Astellas Pharma; Galecto; Sierra Oncology; CTI Biopharma; Incyte; Astex Pharmaceuticals; Jazz Pharmaceuticals; MorphoSys; Celgene; Amgen; Ariad Pharmaceuticals; Alexion Pharmaceuticals; Gilead Sciences; Constellation Pharmaceuticals; Bristol-Myers Squibb","keywords":"Ruxolitinib; Myelofibrosis; Medicine; Placebo; Internal medicine; Phases of clinical research; Double blind; Tofacitinib; Clinical trial; Oncology; Bone marrow; Pathology","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001442654,0.001905809,0.002901171,0.0005321489,0.0005465617,0.001478949,0.001084601,0.002099621,0.008521658],"category_scores_gemma":[0.001161774,0.0007930116,0.001836702,0.0004146723,0.001476668,0.001562383,0.000554918,0.00336648,0.001637615],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006617529,"about_ca_system_score_gemma":0.001295964,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005929645,"about_ca_topic_score_gemma":0.001712208,"domain_scores_codex":[0.9995317,0.0002161048,0.00002083261,0.0001161017,0.00003333175,0.00008190391],"domain_scores_gemma":[0.9994711,0.00009067246,0.0001046215,0.00004677453,0.00004543805,0.0002413953],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9568236,0.01269321,0.0007250286,0.0007510178,0.0008537114,0.0000732247,0.0000923197,0.0003361668,0.007303696,0.0001683629,0.0016154,0.01856425],"study_design_scores_gemma":[0.9562267,0.04083546,0.001423218,0.0000232043,0.0002178462,0.00003511165,0.000021225,0.0002048289,0.0002511559,0.0001212064,0.0006272265,0.00001287455],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9764881,0.004949396,0.001275877,0.001574591,0.0007547934,0.008959377,0.002001103,0.0004533788,0.003543452],"genre_scores_gemma":[0.9746518,0.002840351,0.002994275,0.002648957,0.0004066825,0.009830303,0.002053382,0.00007486323,0.004499368],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.008521658,"threshold_uncertainty_score":0.02850777,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0175712515666619,"score_gpt":0.3232659248153563,"score_spread":0.3056946732486944,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}